# Precision immunotherapy with CAR-T cells in pediatric B-cell acute lymphoblastic leukemia: advances and unanswered challenges

## TL;DR

CAR-T cell therapy is a promising treatment for pediatric B-cell leukemia, but challenges like side effects and high costs remain.

## Contribution

The paper reviews recent advances in CAR-T therapy and highlights next-generation strategies to improve efficacy and safety.

## Key findings

- CD19-targeted CAR T cells like tisagenlecleucel show high remission rates in pediatric B-ALL.
- Multi-targeted CAR-T constructs and armored CAR-T cells are being developed to address limitations like antigen escape and toxicity.
- Universal CAR-T and microenvironment-responsive designs are emerging as potential solutions to improve therapy outcomes.

## Abstract

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking treatment for pediatric B-cell acute lymphoblastic leukemia (B-ALL), especially for patients with relapsed or refractory disease. CD19-targeted CAR T cells, such as tisagenlecleucel, have demonstrated high rates of complete remission and long-lasting responses in clinical trials. However, challenges such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), antigen escape, and T-cell exhaustion hinder its broader clinical application. Recent advances aim to overcome these obstacles by using multi-targeted CAR-T constructs (e.g., CD19/CD22), creating armored CAR-T cells with enhanced cytokine signaling, and developing optimized combination therapies. Next-generation approaches, including universal CAR-T cells and microenvironment-responsive designs, show promise in improving efficacy and safety. Despite these innovations, further research is needed to refine manufacturing processes, reduce costs, and improve long-term outcomes. This review emphasizes the transformative potential of CAR-T therapy for pediatric B-ALL and discusses critical challenges and future directions in the field.